Overview
GMAB market data
Price History
GMAB price chart
Valuation & Profitability
- P/E (TTM)
- 21.20 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $15.36 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.57 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1,337.00 – $2,257.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $114.1K · P/B 3.26 · P/S 4.46.
Company news
Genmab shares are trading lower after the company and AbbVie provided clarification on the primary endpoints from the Phase 3 EPCORE DLBCL-1 study. The study did not meet its primary endpoint.Benzinga · Jul 23, 2026, 8:18 PM
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Globenewswire Inc · Jul 23, 2026, 8:15 PM
GenMab A/S And AbbVie To Submit Data To Peer-Reviewed Medical Journal For Already-Released Phase 3 Trial Data Evaluating Epcoritamab For Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Who Were Ineligible For Autologous Stem Cell TransplantationBenzinga · Jul 23, 2026, 8:10 PM
TD Cowen Upgrades Genmab to Buy, Raises Price Target to $43Benzinga · Jul 22, 2026, 5:28 PM
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsightGlobenewswire Inc · Jul 21, 2026, 6:30 PM
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobenewswire Inc · Jul 21, 2026, 6:30 PM
Genmab Reports Q2 DARZALEX Net Sales Of $4.207B, Up 17.6% YoYBenzinga · Jul 15, 2026, 10:25 AM
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobenewswire Inc · Jul 13, 2026, 5:15 PM
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular LymphomaGlobenewswire Inc · Jul 6, 2026, 6:15 PM
Genmab’s TEPKINLY + R2 Wins EU Approval As First Bispecific Therapy For Relapsed Follicular Lymphoma Following Phase 3 Trial SuccessBenzinga · Jul 6, 2026, 5:55 PM